Vandoeuvre Les Nancy Cedex

• ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting
  2024-514030-20-00 4 2025-08-29 colorectal cancer
• Detection of tumour DNA in the blood of patients receiving standard therapy for hormone receptor-positive (HR+) HER2 low expression (HER2 lo … Recruiting
  2024-515349-41-00 4 2025-07-29 Metastatic Breast Cancer HR+, HER2-
• A Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy in Participants with Non-s … Recruiting
  2024-513682-40-01 5 2025-07-04 Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
• metastatic colorectal cancer Recruiting
  2023-504831-42-00 5 2025-06-27 patient with colorectal cancer with hepatic metastasis
• Phase 3 Study of I-DXd Versus Docetaxel in mCRPC Recruiting
  2024-517423-40-00 5 2025-06-23 Metastatic Castration-Resistant Prostate Cancer
• IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as p … Recruiting
  2024-517325-43-00 4 2025-06-19 multiple myeloma
• JAK inhibitor dose TAPering strategy study in low disease activity rheumatoid arthritis patients. Recruiting
  2023-509788-25-00 6 2025-06-16 Rheumatoid arthritis
• Evaluation of 200 mg of Rituximab every 6 months as maintenance treatment of Rituximab-treated patients with rheumatoid arthritis: a non-inf … Recruiting
  2024-519991-18-00 6 2025-06-16 Rheumatoid Arthritis
• A Phase 3, multicenter, open label, randomized, non-comparative two-arm study of ivosidenib monotherapy (IVO) and azacitidine monotherapy (A … Recruiting
  2023-510155-37-00 5 2025-05-08 Hypomethylating agent (HMA) naive myelodysplastic syndromes Myelodyspl
• ReaLuP : Study on Re-treatment with Radiopharmaceutical Drug [177Lu]Lu-PSMA in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting
  2024-512043-22-00 4 2025-04-11 Metastatic prostate cancer
• Efficacy and safety of bezafibrate 400 mg and bezafibrate 200 mg as adjunctive treatments in patients with primary biliary cholangitis and n … Recruiting
  2023-504086-23-00 5 2025-03-27 Subjects with PBC with a non-optimal response to UDCA.
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• Lutathera for the treatment of recurrent Meningioma (LUMEN-1) Recruiting
  2024-513443-93-00 4 2025-03-10 Recurrent Meningioma without local treatment options (Surgery or Radio
• Open-label study of Asciminib for CML-CP or CML-AP patients with T315I mutation who are resistant, intolerant or ineligible to ponatinib Recruiting
  2024-516049-38-00 4 2025-02-18 CML-CP or CML-AP patients with T315I mutation
• PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatel … Recruiting
  2024-510772-20-00 4 2025-02-06 Rectal cancer locally advanced with microsatellite unstable or mismatc
• Combination of baricitinib and anti-TNF in rheumatoid arthritis Recruiting
  2024-511442-39-00 5 2025-02-05 Rheumatoid arthritis (RA)
• A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting
  2023-510322-32-00 5 2025-01-27 patients with incurable, metastatic/recurrent head and neck squamous c
• A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting
  2023-510323-30-00 5 2025-01-24 First-line treatment of recurrent or metastatic PD-L1+ head and neck s
• Dose individualization of chemotherapy in patients with gastrointestinal cancers lacking a specific liver enzyme Recruiting
  2023-509963-25-00 4 2025-01-17 Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer
• SUPPRESS. Prophylactic frequent premature ventricular complexeS sUPPression on left ventriculaR function impairmEnt in aSymptomatic patientS Recruiting
  2024-516372-14-00 11 2025-01-13 Asymptomatic Patients with frequent PVCs and normal LVEF
• Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting
  2023-509811-98-00 4 2025-01-07 Patients with HER2-positive locally advanced inoperable or metastatic
• Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiorit … Recruiting
  2024-510981-18-00 5 2024-12-12 Multiple Myeloma Multiple myeloma (MM) is a B cell malignancy and is o
• A clinical trial to learn about the effects of YTB in people with difficult to treat active systemic lupus erythematosus (SLE), or active k … Recruiting
  2023-510150-17-00 4 2024-12-11 Active, refractory systemic lupus erythematosus (SLE), and active, re
• A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha … Recruiting
  2024-516109-21-00 5 2024-12-09 Polycythaemia Vera (PV)

Showing 49–72 of 189 trials